Emergency Use of Occlutech® Atrial Flow Regulator Device Facilitates Weaning From Veno-Arterial Extracorporeal Membrane Oxygenation in a Patient With Severe Pulmonary Arterial Hypertension.

Autor: Aregullin EO; Congenital Heart Center, Spectrum Health Helen DeVos Children's Hospital, Grand Rapids, MI, USA.; Pediatrics and Human Development, Michigan State University College of Human Medicine, Grand Rapids, MI, USA., Samuel BP; Congenital Heart Center, Spectrum Health Helen DeVos Children's Hospital, Grand Rapids, MI, USA., Girgis R; Pulmonology, Spectrum Health Medical Group, Grand Rapids, MI, USA.; Department of Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA., Vettukattil JJ; Congenital Heart Center, Spectrum Health Helen DeVos Children's Hospital, Grand Rapids, MI, USA.; Pediatrics and Human Development, Michigan State University College of Human Medicine, Grand Rapids, MI, USA.
Jazyk: angličtina
Zdroj: Journal of intensive care medicine [J Intensive Care Med] 2021 Jun; Vol. 36 (6), pp. 726-728. Date of Electronic Publication: 2021 Apr 15.
DOI: 10.1177/08850666211007809
Abstrakt: Pulmonary arterial hypertension (PAH) is a severe and progressive disease. Treatment options include anti-PAH medications, continuous intravenous therapies, and diuretics. Lung transplant is required in many cases. Atrial septostomy is an under recognized option in symptomatic patients on maximal PAH therapy. However, creating a sustainable and restrictive atrial communication is challenging with existing devices. We describe emergency use of the Occlutech ® Atrial Flow Regulator, a novel device, in a 35-year-old female with PAH supported on veno-arterial extracorporeal membrane oxygenation after postpartum decompensation.
Databáze: MEDLINE